These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19835954)

  • 21. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
    Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
    J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SHP2 sails from physiology to pathology.
    Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
    Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activating mutations in protein tyrosine phosphatase Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to myeloproliferative disorder.
    Xu D; Zheng H; Yu WM; Qu CK
    PLoS One; 2013; 8(5):e63152. PubMed ID: 23675459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SH2 Domain-Containing Phosphatase-SHP2 Attenuates Fibrotic Responses through Negative Regulation of Mitochondrial Metabolism in Lung Fibroblasts.
    Karampitsakos T; Galaris A; Barbayianni I; DeIuliis G; Ahangari F; Sampsonas F; Sotiropoulou V; Aidinis V; Bennett AM; Herazo-Maya JD; Xylourgidis N; Bakakos P; Bouros D; Kaminski N; Tzouvelekis A
    Diagnostics (Basel); 2023 Mar; 13(6):. PubMed ID: 36980473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
    Siegfried A; Cances C; Denuelle M; Loukh N; Tauber M; Cavé H; Delisle MB
    Am J Med Genet A; 2017 Apr; 173(4):1061-1065. PubMed ID: 28328117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth.
    Tajan M; Pernin-Grandjean J; Beton N; Gennero I; Capilla F; Neel BG; Araki T; Valet P; Tauber M; Salles JP; Yart A; Edouard T
    Hum Mol Genet; 2018 Jul; 27(13):2276-2289. PubMed ID: 29659837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma.
    Hu Z; Wang X; Fang H; Liu Y; Chen D; Zhang Q; Liu X; Wei D; Qu C; Wang S
    Oncotarget; 2016 Feb; 7(5):5664-76. PubMed ID: 26673822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain-Specific Serine-47 Modification of Cytochrome
    Kalpage HA; Wan J; Morse PT; Lee I; Hüttemann M
    Cells; 2020 Aug; 9(8):. PubMed ID: 32781572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
    Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
    J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
    Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein-tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst.
    Li XJ; Goodwin CB; Nabinger SC; Richine BM; Yang Z; Hanenberg H; Ohnishi H; Matozaki T; Feng GS; Chan RJ
    J Biol Chem; 2015 Feb; 290(7):3894-909. PubMed ID: 25538234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.
    Kontaridis MI; Yang W; Bence KK; Cullen D; Wang B; Bodyak N; Ke Q; Hinek A; Kang PM; Liao R; Neel BG
    Circulation; 2008 Mar; 117(11):1423-35. PubMed ID: 18316486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [SOS1 mutation: a new cause of Noonan syndrome].
    Serrano-Martín MM; Martínez-Aedo MJ; Tartaglia M; López-Siguero JP
    An Pediatr (Barc); 2008 Apr; 68(4):365-8. PubMed ID: 18394382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
    Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W
    J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome.
    Nakamura T; Colbert M; Krenz M; Molkentin JD; Hahn HS; Dorn GW; Robbins J
    J Clin Invest; 2007 Aug; 117(8):2123-32. PubMed ID: 17641779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
    Binder G
    Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis.
    Tzouvelekis A; Yu G; Lino Cardenas CL; Herazo-Maya JD; Wang R; Woolard T; Zhang Y; Sakamoto K; Lee H; Yi JS; DeIuliis G; Xylourgidis N; Ahangari F; Lee PJ; Aidinis V; Herzog EL; Homer R; Bennett AM; Kaminski N
    Am J Respir Crit Care Med; 2017 Feb; 195(4):500-514. PubMed ID: 27736153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.